The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2011
Filed:
May. 14, 2010
Allen Radin, New York, NY (US);
Sean Stevens, San Diego, CA (US);
Tammy T. Huang, Goldens Bridge, NY (US);
Joel H. Martin, Putnam Valley, NY (US);
Jeanette L. Fairhurst, White Plains, NY (US);
Ashique Rafique, Yonkers, NY (US);
Eric Smith, New York, NY (US);
Kevin J. Pobursky, Beacon, NY (US);
Nicholas J. Papadopoulos, LaGrangeville, NY (US);
James P. Fandl, LaGrangeville, NY (US);
Gang Chen, Yorktown Heights, NY (US);
Margaret Karow, Camarillo, CA (US);
Allen Radin, New York, NY (US);
Sean Stevens, San Diego, CA (US);
Tammy T. Huang, Goldens Bridge, NY (US);
Joel H. Martin, Putnam Valley, NY (US);
Jeanette L. Fairhurst, White Plains, NY (US);
Ashique Rafique, Yonkers, NY (US);
Eric Smith, New York, NY (US);
Kevin J. Pobursky, Beacon, NY (US);
Nicholas J. Papadopoulos, LaGrangeville, NY (US);
James P. Fandl, LaGrangeville, NY (US);
Gang Chen, Yorktown Heights, NY (US);
Margaret Karow, Camarillo, CA (US);
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Abstract
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.